Tolerability and Safety of Transcranial Photobiomodulation for Mood and Anxiety Disorders

Paolo Cassano, Richard Norton, Marco Antonio Caldieraro, Farzan Vahedifard, Fernando Vizcaino, Kayla Marie McEachern, Dan Iosifescu

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Introduction: Mood and anxiety disorders are a prevalent and significant leading cause of years lived with a disability worldwide. Existing antidepressants drugs are only partially effective, having burdensome side effects. One-third of patients do not achieve remission after several adequate antidepressant trials, and relapses of depression are frequent. Psychotherapies for depression are limited by the lack of trained professionals, and further by out-of-pocket prohibitive costs. Existing FDA-approved, device-based interventions are either invasive or only administered in the office. Transcranial photobiomodulation (t-PBM) with near-infrared (NIR) light may be a promising treatment option for mood and anxiety disorders. Due to its low cost, and ease of self-administration, t-PBM has the potential to become widely accessible. The safety profile of t-PBM is a relevant factor for widespread use and administration. Aim: To further investigate the t-PBM safety profile, this study aims to evaluate the tolerability and safety of t-PBM for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD). Method: We completed a systematic analysis of the side effects from repeated sessions of t-PBM in three studies: an open-label study for GAD (LIGHTEN GAD) and two randomized control studies for MDD (ELATED-2; ELATED-3). Overall, 80 subjects were studied. Result: Our results show that a low dose of NIR per t-PBM session can be administered with increasing frequency (up to daily sessions) and for several weeks (up to 12 weeks) without a corresponding increase in the occurrence or severity of adverse events. Additionally, there were no significant predictors for the variance in the number of reported adverse events (such as age, sex or diagnosis). Conclusion: The literature indicates that higher dosages of transcranial NIR could lead to greater antidepressant and anxiolytic effects; this study did not find any correlation between the increasing number of t-PBM sessions and the occurrence of adverse events.

Original languageEnglish
Article number507
JournalPhotonics
Volume9
Issue number8
DOIs
StatePublished - Aug 2022

Keywords

  • anxiety
  • depression
  • neuromodulation
  • photobiomodulation

Fingerprint

Dive into the research topics of 'Tolerability and Safety of Transcranial Photobiomodulation for Mood and Anxiety Disorders'. Together they form a unique fingerprint.

Cite this